1. Home
  2. QRVO vs STVN Comparison

QRVO vs STVN Comparison

Compare QRVO & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qorvo Inc.

QRVO

Qorvo Inc.

HOLD

Current Price

$88.10

Market Cap

8.3B

Sector

Technology

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$20.96

Market Cap

7.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
QRVO
STVN
Founded
1957
1949
Country
United States
Italy
Employees
N/A
N/A
Industry
Semiconductors
Containers/Packaging
Sector
Technology
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
7.4B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
QRVO
STVN
Price
$88.10
$20.96
Analyst Decision
Hold
Buy
Analyst Count
14
4
Target Price
$98.23
$25.38
AVG Volume (30 Days)
1.1M
329.9K
Earning Date
01-27-2026
11-06-2025
Dividend Yield
N/A
0.30%
EPS Growth
N/A
19.61
EPS
2.30
0.60
Revenue
$3,663,072,000.00
$1,373,219,524.00
Revenue This Year
$3.31
$8.42
Revenue Next Year
$2.34
$9.52
P/E Ratio
$38.32
$34.98
Revenue Growth
N/A
6.97
52 Week Low
$49.46
$17.81
52 Week High
$106.30
$28.00

Technical Indicators

Market Signals
Indicator
QRVO
STVN
Relative Strength Index (RSI) 50.24 39.09
Support Level $85.03 $20.62
Resistance Level $90.30 $23.88
Average True Range (ATR) 1.89 1.14
MACD 0.53 -0.08
Stochastic Oscillator 66.56 10.68

Price Performance

Historical Comparison
QRVO
STVN

About QRVO Qorvo Inc.

Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: